Table 1.
Clinical, pathological, and demographic characteristics and association with PIK3CA mutation.
| Variable Categories | PIK3CA Evaluation | Total Cases n = 95 |
p-Value | |
|---|---|---|---|---|
| WT (n = 58) | MUT (n = 37) | |||
| n (%) | n (%) | n (%) | ||
| Gender | ||||
| Male | 45 (77.6%) | 25 (67.6%) | 70 (73.7%) | 0.2795 |
| Female | 13 (22.4%) | 12 (32.4%) | 25 (26.3%) | |
| Age at diagnosis | ||||
| Mean (Standard Deviation) | 62 (10.7) | 62 (12.7) | 62 (11.5) | 0.9740 |
| ≥65 Years | 24 (41.4%) | 12 (32.4%) | 36 (37.9%) | 0.3807 |
| <65 Years | 34 (58.6%) | 25 (67.6%) | 59 (62.1%) | |
| Consumption habits (tobacco and/or alcohol) | ||||
| Active consumption | 44 (75.9%) | 22 (59.5%) | 66 (69.5%) | 0.0325 * |
| Alcohol active | 18 (31.0%) | 10 (27%) | 28 (29.5%) | |
| Tobacco active | 7 (12.1%) | 1 (2.7%) | 8 (8.4%) | |
| Both active | 19 (32.8%) | 11 (29.7%) | 30 (39.6%) | |
| No consumption | 9 (15.5%) | 13 (35.1%) | 22 (23.2%) | |
| Never | 5 (8.6%) | 10 (27%) | 15 (15.8%) | |
| Nonactive | 4 (6.9%) | 3 (8.1%) | 7 (7.4%) | |
| No data | 5 (8.6%) | 2 (5.4%) | 7 (7.4%) | |
| Tumour Anatomic region | ||||
| Oropharynx | 46 (79.3%) | 29 (78.4%) | 75 (78.9%) | 0.9135 |
| Oral cavity | 12 (20.7%) | 8 (21.6%) | 20 (21.1%) | |
| Tumour stage | ||||
| I | 4 (6.9%) | 4 (10.8%) | 8 (8.4%) | 0.9342 |
| II | 11 (19%) | 8 (21.6%) | 19 (20.0%) | |
| III | 16 (27.6%) | 10 (27.0%) | 26 (27.4%) | |
| IV | 25 (43.1%) | 15 (40.5%) | 40 (42.1%) | |
| No data | 2 (3.4%) | 0 | 2 (2.1%) | |
| p16 IHQ | ||||
| HNSCC p16(−) | 29 (50.0%) | 24 (64.9%) | 53 (55.8%) | 0.1627 |
| HNSCC p16(+) | 25 (43.1%) | 11 (29.7%) | 36 (37.9%) | |
| No data | 4 (6.9%) | 2 (5.4%) | 6 (6.3%) | |
| HPV infection | ||||
| HPV16 DNA(−) | 15 (25.9%) | 12 (32.4%) | 27(28.4%) | 0.4887 |
| HPV16 DNA(+) | 43 (74.1%) | 25 (67.6%) | 68 (71.6%) | |
| Single infection | 39 (90.7%) | 23 (92.0%) | 62 (91.2%) | |
| Co infection with other HR/LR HPV | 4 (9.3%) | 2 (8%) | 6 (8.8%) | |
| Primary Treatment | ||||
| Surgery | 1 (1.7%) | 2 (5.4%) | 3 (3.2%) | 0.7376 |
| Radiotherapy (RT) | 10 (17.2%) | 6 (16.2%) | 16 (16.8%) | |
| Chemotherapy (CTX) | 46 (79.3%) | 29 (78.4%) | 75 (78.9%) | |
| CTX + RT | 26 (56.5%) | 12 (41.4%) | 38 (50.7%) | |
| Surgery + RT | 9 (19.6%) | 11 (37.9%) | 20 (26.7%) | |
| Surgery + CTX | 11 (23.9%) | 6 (20.7%) | 17(22.7%) | |
| No data | 1 (1.7%) | 0 | 1 (1.1%) | |
| Treatment response | ||||
| Complete | 38 (65.5%) | 28 (75.7%) | 66 (69.5%) | 0.5190 |
| Persistence | 11 (19.0%) | 6 (16.2%) | 17 (17.9%) | |
| No data | 9 (15.5%) | 3 (8.1%) | 12 (12.6%) | |
Legend: No data = no information available; RT = Radiotherapy; CTX = Chemotherapy; * p-value calculate for active vs. no consumption group.